Prognostic Test
Cutaneous Squamous Cell Carcinoma (cSCC)
Key Facts
About AMLo Biosciences
AMLo Biosciences is a private, pre-revenue diagnostics company developing innovative prognostic tests to better stratify cancer patients by their individual risk of disease progression. Its lead program targets early-stage melanoma, where over 90% of patients are currently over-treated, aiming to redirect resources to high-risk individuals and generate significant healthcare savings. Founded by a team with strong oncology and biotech experience, the company has secured £6.4 million in combined research and equity funding to advance its pipeline, which also includes tests for cutaneous squamous cell carcinoma (cSCC) and oropharyngeal squamous cell carcinoma (OPSCC).
View full company profileAbout AMLo Biosciences
AMLo Biosciences is a private, pre-revenue diagnostics company developing innovative prognostic tests to better stratify cancer patients by their individual risk of disease progression. Its lead program targets early-stage melanoma, where over 90% of patients are currently over-treated, aiming to redirect resources to high-risk individuals and generate significant healthcare savings. Founded by a team with strong oncology and biotech experience, the company has secured £6.4 million in combined research and equity funding to advance its pipeline, which also includes tests for cutaneous squamous cell carcinoma (cSCC) and oropharyngeal squamous cell carcinoma (OPSCC).
View full company profileTherapeutic Areas
Other Cutaneous Squamous Cell Carcinoma (cSCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| BCA101 | Bicara Therapeutics | Phase 1/2 |
| UNLOXCYT™ (cosibelimab-ipdl) | Fortress Biotech | Approved/Commercial |